NVAX logo

Novavax Inc. (NVAX)

$7.96

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on NVAX

Market cap

$1.31B

EPS

-0.29

P/E ratio

--

Price to sales

5.08

Dividend yield

--

Beta

2.65097

Price on NVAX

Previous close

$8.06

Today's open

$8.05

Day's range

$7.88 - $8.14

52 week range

$6.20 - $13.39

Profile about NVAX

CEO

JOHN C. JACOBS

Employees

749

Headquarters

Gaithersburg, MD

Exchange

Nasdaq Global Select

Shares outstanding

165009009

Issue type

Common Stock

NVAX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on NVAX

Novavax Eyes New Partnerships as Sanofi Advances COVID-Flu Vaccine Trial

Novavax NASDAQ: NVAX is looking to expand partnerships around its vaccine technology while advancing a potential C. difficile vaccine and supporting partner Sanofi's development of a combination COVID-19 and flu shot, executives said at the Jefferies 2026 Global Healthcare Conference in London.

news source

MarketBeat • Nov 17, 2026

news preview

Novavax to Participate in Jefferies London Healthcare Conference

GAITHERSBURG, Md., Nov. 11, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the following upcoming investor conference: Jefferies London Healthcare Conference, London, United KingdomFireside chat on Tuesday, November 17, 2026, at 5:00 p.m.

news source

PRNewsWire • Nov 11, 2026

news preview

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

news source

Zacks Investment Research • Nov 10, 2026

news preview

Novavax Q3 Earnings Call Highlights

Novavax NASDAQ: NVAX raised its 2026 revenue framework after partner Sanofi began a late-stage trial of a combination influenza and COVID-19 vaccine in Europe, triggering a $125 million milestone payment for the vaccine technology company.

news source

MarketBeat • Nov 6, 2026

news preview

NVAX Stock Falls 8% Despite Q3 Earnings & Sales Beat, Costs Decline

Novavax shares fall 8% despite Q3 earnings and revenue beat as costs decline, while a Sanofi milestone drives a sharp increase in its 2026 outlook.

news source

Zacks Investment Research • Nov 6, 2026

news preview

Novavax, Inc. (NVAX) Q3 2026 Earnings Call Transcript

Novavax, Inc. (NVAX) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 5, 2026

news preview

Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights

Reports total revenue of $68 million for the third quarter of 2026 Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D and SG&A expense guidance by $5 million at mid-point  In October, Novavax earned a $125 million milestone upon Sanofi's launch of Phase 3 influenza-COVID-19 combination vaccine trial in Europe Sanofi confirms their intent to initiate a U.S. Phase 3 influenza-COVID-19 combination vaccine trial in 2027 to support U.S. approval Differentiated C. difficile vaccine program anticipated to advance into the clinic as early as 2027 Multiple Novavax and partner-led experiments with Matrix-M ® currently underway in a wide array of infectious disease targets and oncology models Company to host conference call today at 8:30 a.m.

news source

PRNewsWire • Nov 5, 2026

news preview

Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates

Novavax (NVAX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.62 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026

GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the Company plans to release its third quarter 2026 financial results before the open of the U.S. financial markets on Thursday, November 5, 2026.

news source

PRNewsWire • Oct 29, 2026

news preview

Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe

The global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden of disease 1 The combination vaccine candidate evaluated in this trial pairs Sanofi's leading high-dose flu vaccine with Novavax's differentiated COVID-19 vaccine Significant potential value remains in Sanofi partnership via additional future opportunities for milestones and royalties GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax (Nasdaq: NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's COVID-19 vaccine, Nuvaxovid™.

news source

PRNewsWire • Oct 29, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Novavax Inc.

Open an M1 investment account to buy and sell Novavax Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in NVAX on M1